New combination treatments in the management of diabetes: focus on sitagliptin – metformin
Authors:
Open Access
- 1 August 2008
- journal article
- review article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 4 (4) , 743-751
Abstract
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishingKeywords
This publication has 45 references indexed in Scilit:
- Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2006
- Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatmentsBiochemical and Biophysical Research Communications, 2004
- Treating to goal: challenges of current managementEuropean Journal of Endocrinology, 2004
- Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed DiabetesJAMA, 2004
- Enhancing Incretin Action for the Treatment of Type 2 DiabetesDiabetes Care, 2003
- The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetesDiabetologia, 2003
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine, 2002
- Oral Antihyperglycemic Therapy for Type 2 DiabetesJAMA, 2002
- Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic SubjectsDiabetes Care, 2001
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000